SCHEMBL5142176

SCHEMBL5142176

CNCC(C)(O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.56
KCNN4 O15554 2/20 0.43
HIF1A Q16665 1/20 0.41
ALDH1A1 P00352 3/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 6/20 0.40
MEN1 O00255 4/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
ESR2 Q92731 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9413960 0.98 CYP2C19 (0.54) CYP2C19KCNN4HIF1AALDH1A1TAAR1
Hydrochloric Acid SCHEMBL9413928 0.96 CYP2C19 (0.53) CYP2C19KCNN4HIF1AALDH1A1TAAR1
SCHEMBL9413932 0.92 CYP2C19 (0.50) CYP2C19KCNN4HIF1AALDH1A1TAAR1
SCHEMBL10156588 0.80 CYP2C19 (0.50) CYP2C19KCNN4HIF1AALDH1A1TAAR1
SCHEMBL3444934 0.80 KCNN4 (0.44) CYP2C19KCNN4HIF1AALDH1A1TAAR1
SCHEMBL5035455 0.80 MEN1 (0.53) CYP2C19KCNN4ALDH1A1KMT2AMEN1
SCHEMBL8028843 0.79 TAAR1 (0.56) CYP2C19KCNN4HIF1AALDH1A1TAAR1
SCHEMBL28333306 0.79 CYP2C19 (0.53) CYP2C19HIF1AALDH1A1TAAR1ALOX15
SCHEMBL2013207 0.79 CYP2C19 (0.53) CYP2C19KCNN4HIF1AALDH1A1TAAR1
SCHEMBL16312162 0.79 NPSR1 (0.55) CYP2C19HIF1ATAAR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043037-A1 PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2007-02-22 US claimed
EP-1527034-A1 A PROCESS FOR THE OPTICAL RESOLUTION OF A PRECURSOR OF SCLAREOLIDE FIRMENICH SA (CH) 2005-05-04 EP disclosed
WO-2004013069-A1 A PROCESS FOR THE OPTICAL RESOLUTION OF A PRECURSOR OF SCLAREOLIDE FIRMENICH SA (CH) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043037-A1 PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R CYP2C19 1021/4885KCNN4 3101/4885HIF1A 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.